Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Growth in sales volumes in the ischemic heart disease, cardiac rhythm management and cardiovascular surgery-related businesses, growth in revenue from medical equipment-related products, expansion of business with existing customers and acquisition of new customers, and the addition of 株式会社プラステンメディカル to the group
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥90,391 million (YoY +11.0%) |
| Operating profit | ¥3,020 million (YoY +7.6%) |
| Ordinary income | ¥3,060 million (YoY +7.9%) |
| Profit attributable to owners of the parent | ¥2,118 million (YoY +4.9%) |
| Net income per share | ¥75.98 |
| Operating Margin | 3.3 |
| Equity ratio | End of the current fiscal period 46 / End of previous period 51.6 |
| Total assets | ¥50,632 million |
| Net assets | ¥23,290 million |
| Cash flows from operating activities | ¥2,930 million |
| Cash flows from investing activities | ¥-132 million |
| Cash flows from financing activities | ¥-3,076 million |
| Cash and cash equivalents at end of period | ¥10,931 million |
| Full-year earnings forecast | Net Sales ¥100,000 million (YoY +10.6%) / Operating profit ¥3,350 million (YoY +10.9%) / Ordinary income ¥3,380 million (YoY +10.4%) / Net income ¥2,210 million (YoY +4.3%) |
| Annual Dividend Forecast | ¥54 → ¥55 |
| Payout ratio | 71.1 |
| Shareholder Return Policy | Continue stable shareholder returns with a dividend payout ratio of at least 30% |
| Depreciation and amortization | ¥300,084 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount ¥10,390 thousand, Item Insurance surrender value / Amount ¥24,813 thousand / Extraordinary loss Item Office relocation expenses / Amount ¥11,366 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 1 company newly included: 株式会社プラステンメディカル; 1 company excluded: 株式会社エムシーアイ (due to its merger with テスコ株式会社) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 30,503,310 shares |
| Treasury Shares at Period-End | 3,004,474 shares |
| Factors Behind Changes in Business Performance | Growth in sales volumes in the ischemic heart disease, cardiac rhythm management and cardiovascular surgery-related businesses, growth in revenue from medical equipment-related products, expansion of business with existing customers and acquisition of new customers, and the addition of 株式会社プラステンメディカル to the group |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales volumes increased in the core ischemic heart disease, cardiac rhythm management and cardiovascular surgery-related businesses, while revenue from medical equipment-related products also grew. In addition to expanding business with existing customers and acquiring new customers, the company advanced proposals offering high added value and added 株式会社プラステンメディカル to the group.